SOX2 and neoplasm: Although there were only 8 HGSOC cases enrolled in this cohort, similar trend could be also found that when much more pluripotent makers highly expressed in the tumor tissues, the HGSOC patients might have much worse clinical outcome compared with those with no or less markers expressed (p = 0.007 for OCT4, 0.054 for SOX2, 0.053 for NANOG, and 0.007 for at least two vs. less, Additional file 14: Figure S13).